Welcome to the all-new Vetlearn

  • Vetlearn is getting a new home. Starting this fall,
    Vetlearn becomes part of the NAVC VetFolio family.

    You'll have access to the entire Compendium and
    Veterinary Technician archives and get to explore
    even more ways to learn and earn CE by becoming
    a VetFolio subscriber. Subscriber benefits:
  • Over 500 hours of interactive CE Videos
  • An engaging new Community for tough cases
    and networking
  • Three years of NAVC Conference Proceedings
  • All-new articles (CE and other topics) for the entire
    healthcare team

To access Vetlearn, you must first sign in or register.


  • Registration for new subscribers will open in September 2014!
  • Watch for additional exciting news coming soon!
Become a Member

Reference Desk November 2011

FDA Approves First Drug to Treat Cushing’s Disease in Horses

    WASHINGTON, DC, November 17, 2011—The FDA announced today the approval of Prascend (pergolide mesylate) for the control of clinical signs associated with pituitary pars intermedia dysfunction (PPID or Equine Cushing’s disease) in horses. Prascend is the first drug approved for use in horses to treat Cushing’s disease, a common disease of older horses that results in significant morbidity and mortality if left untreated.

    Pergolide mesylate is a dopamine agonist that is believed to work by stimulating dopamine receptors in horses with PPID. It has been shown to decrease the plasma levels of adrenocorticotropic hormone (ACTH), melanocyte stimulating hormone (MSH), and other pro-opiomelanocortin peptides.

    Equine Cushing’s disease usually affects horses in their mid-to late-years of life. Diagnosis is made by a veterinarian using a combination of clinical findings and diagnostic testing. Signs of the equine disease include a coat of long curly hair that does not shed properly, excessive water-drinking and urination, abnormal fat distribution, muscle loss, excessive sweating, general malaise, chronic laminitis, and a compromised immune system (which can lead to respiratory ailments, skin infections, hoof abscesses and tooth infections).

    Safety and effectiveness of Prascend was supported by a 6-month field study of 122 horses. Success was measured by improvements in both endocrinology testing (ACTH test) and clinical signs related to PPID (abnormal hair growth and shedding, excessive sweating, urination, and water-drinking, abnormal fat distribution, and/or muscle wasting). Based on endocrine testing and investigators’ clinical assessment scores, 86 (76.1%) of the 113 evaluable cases were treatment successes.

    The most common adverse effects seen were loss of appetite, lameness, diarrhea, colic and lethargy.

    Prascend is manufactured for Boehringer Ingelheim Vetmedica Inc. of St. Joseph, Missouri.

    Source: Food and Drug Administration


    Did you know... All feedstuffs, including forages and concentrates, should be evaluated for their nutritional contributions before they are fed to a patient with equine metabolic syndrome.Read More

    These Care Guides are written to help your clients understand common conditions. They are formatted to print and give to your clients for their information.

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More